Recent developments and application of metabolomics in cancer diseases

      Metabolomics studies provide useful information about health and disease status. Metabolite based investigations on various cancers is a powerful approach to diagnosis, prognosis and therapy of cancer diseases. Recently by using advanced analytical techniques such as NMR and MS and its hyphenation methods, global metabolic profiling of diseases has been possible. It is predictable that international contributions and software developments in the future will lead to accurate instrumental analysis based on  a large number of  human samples that finally will improve validation methods and reach this field from the research phase to the clinical phase. In this review, we also discussed the latest developments in analytical methods, application of data analysis, investigation of useful databases and the curent application of metabolomics in cancer diseases that have led to the identification of related biomarkers. In continuation, we listed biomarkers involved in cancer diseases that have been published during recent years.

Effect of ghrelin on serum metabolites in Alzheimer’s disease model rats; a metabolomics studies based on 1H-NMR technique

Objective(s): Alzheimer’s disease (AD) is dysfunction of the central nervous system and as a neurodegenerative disease. The objective of this work is to investigate metabolic profiling in the serum of animal models of AD compared to healthy controls and then to peruse the role of ghrelin as a therapeutic approach for the AD.Materials and Methods: Nuclear magnetic resonance (NMR) technique was used for identification of metabolites that are differentially expressed in the serum of a rat model of the AD with or without ghrelin treatment. Using multivariate statistical analysis, models were built and indicated.Results: There were significant differences and high predictive power between AD and ghrelin-treated groups. The area under curve (AUC) of receiver operating characteristic (ROC) curve and Q2 were 0.870 and 0.759, respectively. A biomarker panel consisting of 14 metabolites was identified to discriminate the AD from the control group. Another panel of 12 serum metabolites was used to differentiate AD models from treated models. Conclusion: Both panels had good agreements with clinical diagnosis. Analysis of the results displayed that ghrelin improved memory and cognitive abilities. Affected pathways by ghrelin included oxidative stress, and osteoporosis pathways and vascular risk factors

Investigation of metabonomics technique by analyze of NMR data, which method is better? Mean center or auto scale?

The factors such as disease can disrupt homeostasis, resulting in perturbations of endogenous biochemicals that are involved in key metabolic profiles. Metabonomics is useful technique to quantitative description of endogenous metabolites present in a biological sample such as urine, plasma and tissue. High resolution 1H nuclear magnetic resonance (NMR)-based metabonomics is a technique used to analyze and interpret multivariate metabolic data that correlate with changes of physiological conditions. Before any explanation for metabolite data, preprocessing the spectroscopic data is essential. In this paper, we show scaling effects in metabonomics investigation of patients diagnosed with Crohn's and Celiac disease. two techniques of scaling were applied as follows: mean centering and auto scaling. Results reveal that the mean centering is more useful to segregate patients from healthy subjects in the data set of Crohn's and Celiac disease

suppl._Table_1 – Supplemental material for Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study

<p>Supplemental material, suppl._Table_1 for Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study by Reyhaneh Farrokhi Yekta, Afsaneh Arefi Oskouie, Mostafa Rezaei Tavirani, Mohammad R. Mohajeri-Tehrani and Ahmad R. Soroush in The International Journal of Biological Markers</p

suppl._Figure_2 – Supplemental material for Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study

<p>Supplemental material, suppl._Figure_2 for Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study by Reyhaneh Farrokhi Yekta, Afsaneh Arefi Oskouie, Mostafa Rezaei Tavirani, Mohammad R. Mohajeri-Tehrani and Ahmad R. Soroush in The International Journal of Biological Markers</p

suppl._Figure_1 – Supplemental material for Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study

<p>Supplemental material, suppl._Figure_1 for Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study by Reyhaneh Farrokhi Yekta, Afsaneh Arefi Oskouie, Mostafa Rezaei Tavirani, Mohammad R. Mohajeri-Tehrani and Ahmad R. Soroush in The International Journal of Biological Markers</p